Company profile
Kure Cells, Inc.
Privately held: no public share price (Kure Cells (Cleveland, OH, founded 2021) is a privately held CAR-T manufacturing biotech (UF-KURE-BCMA for multiple myeloma), most recently raising $10M (medpath.com, kurecells.bio). Distinct from the similarly named "Kura Oncology"; no public listing found. Sources: https://clinicaltrials.gov/study/NCT07611149 Entity resolved by asset-pipeline-v2.)
Assets
(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
| Target & Modality | |||
|---|---|---|---|
| Phase 1 | BCMACell therapy | Multiple Myeloma |
Upcoming events
Research
Sign in to access ResearchUnlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Research
Sign in to access ResearchUnlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.